# Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

> **NCT02155660** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2255 (actual)

## Conditions studied

- Moderate to Very Severe Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Benralizumab Arm A
- **DRUG:** Benralizumab Arm B
- **DRUG:** Benralizumab Arm C
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02155660
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-25
- **Primary completion:** 2018-04-09
- **Final completion:** 2018-04-09
- **Target enrollment:** 2255 (ACTUAL)
- **Last updated:** 2019-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02155660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02155660, "Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02155660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*